Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice

Neuroscience

Volumn 324, Issue , 2016, Pages 20-28

  Jeon, J ^a   Kim, W ^a   Jang, J ^a   Isacson, O ^b   Seo, H ^a  

^a Hanyang University   (South Korea)

^b MCLEAN HOSPITAL   (United States)

Author keywords

BDNF; Gene transfer; Motor behavior improvement; Proteasome activator; Ubiquitin proteasome system

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ENZYME ACTIVATOR; LENTIVIRUS VECTOR; MESSENGER RNA; PEPTIDYL GLUTAMYL PREFERRING HYDROLYTIC PROTEASOME; PROTEASOME; PROTEASOME ACTIVATOR 28GAMMA; UBIQUITIN; UNCLASSIFIED DRUG; AUTOANTIGEN; HTT PROTEIN, HUMAN; HUNTINGTIN; KI ANTIGEN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; BRAIN TISSUE; CELL INCLUSION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION; GENE TRANSFER; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRASTRIATAL DRUG ADMINISTRATION; LATENT PERIOD; MALE; MOTOR COORDINATION; MOUSE; MOUSE MUTANT; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; YAC128 MOUSE; ADMINISTRATION AND DOSAGE; ANIMAL; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; HUNTINGTON DISEASE; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; AUTOANTIGENS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; INCLUSION BODIES; MALE; MICE, TRANSGENIC; MOTOR ACTIVITY; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; ROTAROD PERFORMANCE TEST; TREATMENT OUTCOME;

EID: 84960935453     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.02.054     Document Type: Article

References (39)

1. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
2. Baquet Z.C., Gorski J.A., Jones K.R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 2004, 24:4250-4258.
3. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
4. Craiu A., Gaczynska M., Akopian T., Gramm C.F., Fenteany G., Goldberg A.L., Rock K.L. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997, 272:13437-13445.
5. de Almeida L.P., Ross C.A., Zala D., Aebischer P., Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002, 22:3473-3483.
6. de Pril R., Hobo B., van Tijn P., Roos R.A., van Leeuwen F.W., Fischer D.F. Modest proteasomal inhibition by aberrant ubiquitin exacerbates aggregate formation in a Huntington disease mouse model. Mol Cell Neurosci 2010, 43:281-286.
7. Droggiti A., Ho C.C.-Y., Stefanis L., Dauer W.T., Rideout H.J. Targeted disruption of neuronal 19S proteasome subunits induces the formation of ubiquitinated inclusions in the absence of cell death. J Neurochem 2011, 119:630-643.
8. Ferrer I., Goutan E., Marin C., Rey M.J., Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000, 866:257-261.
9. Francia N., Cirulli F., Chiarotti F., Antonelli A., Aloe L., Alleva E. Spatial memory deficits in middle-aged mice correlate with lower exploratory activity and a subordinate status: role of hippocampal neurotrophins. Eur J Neurosci 2006, 23:711-728.
10. Freudenburg W., Gautam M., Chakraborty P., James J., Richards J., Salvatori A.S., Baldwin A., Schriewer J., Buller R.M.L., Corbett J.A., Skowyra D. Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNβ in mouse pancreatic β-cells. PLoS One 2013, 8:e52408.
11. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
12. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., Wheeler V.C., Persichetti F., MacDonald M.E. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 2003, 12:497-508.
13. Group THsDS A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
14. Her L.S., Goldstein L.S. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 2008, 28:13662-13672.
15. Hermel E., Gafni J., Propp S.S., Leavitt B.R., Wellington C.L., Young J.E., Hackam A.S., Logvinova A.V., Peel A.L., Chen S.F., Hook V., Singaraja R., Krajewski S., Goldsmith P.C., Ellerby H.M., Hayden M.R., Bredesen D.E., Ellerby L.M. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 2004, 11:424-438.
16. Kaspar B.K., Vissel B., Bengoechea T., Crone S., Randolph-Moore L., Muller R., Brandon E.P., Schaffer D., Verma I.M., Lee K.F., Heinemann S.F., Gage F.H. Adeno-associated virus effectively mediates conditional gene modification in the brain. Proc Natl Acad Sci U S A 2002, 99:2320-2325.
17. Kells A.P., Henry R.A., Connor B. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther 2008, 15:966-977.
18. Kisselev A.F., Akopian T.N., Castillo V., Goldberg A.L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 1999, 4:395-402.
19. Kisselev A.F., Garcia-Calvo M., Overkleeft H.S., Peterson E., Pennington M.W., Ploegh H.L., Thornberry N.A., Goldberg A.L. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 2003, 278:35869-35877.
20. Kisselev A.F., Callard A., Goldberg A.L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006, 281:8582-8590.
21. Mao I., Liu J., Li X., Luo H. REGgamma, a proteasome activator and beyond?. Cell Mol Life Sci 2008, 65:3971-3980.
22. McCoy M.K., Ruhn K.A., Martinez T.N., McAlpine F.E., Blesch A., Tansey M.G. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther 2008, 16:1572-1579.
23. Menalled L., El-Khodor B.F., Patry M., Suarez-Farinas M., Orenstein S.J., Zahasky B., Leahy C., Wheeler V., Yang X.W., MacDonald M., Morton A.J., Bates G., Leeds J., Park L., Howland D., Signer E., Tobin A., Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 2009, 35:319-336.
24. Palfi S., Brouillet E., Jarraya B., Bloch J., Jan C., Shin M., Conde F., Li X.J., Aebischer P., Hantraye P., Deglon N. Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther 2007, 15:1444-1451.
25. Petrucelli L., Dawson T.M. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 2004, 36:315-320.
26. Rechsteiner M., Realini C., Ustrell V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J 2000, 345(Pt 1):1-15.
27. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat Med 2004, 10:S10-S17.
28. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004, 56:319-328.
29. Seo H., Sonntag K.C., Kim W., Cattaneo E., Isacson O. Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS One 2007, 2:e238.
30. Seo H., Kim W., Isacson O. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum Mol Genet 2008, 17:3144-3153.
31. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.-Z., Li X.-J., Simpson E.M., Gutekunst C.-A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12:1555-1567.
32. Smith D.M., Kafri G., Cheng Y., Ng D., Walz T., Goldberg A.L. ATP binding to PAN or the 26S ATPases Causes Association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell 2005, 20:687-698.
33. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., Kennard C., Hicks S.L., Fox N.C., Scahill R.I., Borowsky B., Tobin A.J., Rosas H.D., Johnson H., Reilmann R., Landwehrmeyer B., Stout J.C. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009, 8:791-801.
34. Van Raamsdonk J.M., Pearson J., Rogers D.A., Bissada N., Vogl A.W., Hayden M.R., Leavitt B.R. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 2005, 14:1379-1392.
35. Xie Y., Hayden M.R., Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 2010, 30:14708-14718.
36. Zhang Z., Zhang R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J 2008, 27:852-864.
37. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000, 23:217-247.
38. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
39. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998, 72:9873-9880.